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Abstract
Hidden Markov jump processes are an attrac-
tive approach for modeling clinical disease
progression data because they are explain-
able and capable of handling both irregularly
sampled and noisy data. Most applications
in this context consider time-homogeneous
models due to their relative computational
simplicity. However, the time homogeneous
assumption is too strong to accurately model
the natural history of many diseases. More-
over, the population at risk is not homoge-
neous either, since disease exposure and sus-
ceptibility can vary considerably. In this pa-
per, we propose a piece-wise stationary tran-
sition matrix to explain the heterogeneity in
time. We propose a hierarchical structure for
the heterogeneity in population, where prior
information is considered to deal with unbal-
anced data. Moreover, an efficient, scalable
EM algorithm is proposed for inference. We
demonstrate the feasibility and superiority
of our model on a cervical cancer screening
dataset from the Cancer Registry of Norway.
Experiments show that our model outper-
forms state-of-the-art recurrent neural net-
work models in terms of prediction accu-
racy and significantly outperforms a standard
hidden Markov jump process in generating
Kaplan-Meier estimators.
1 Introduction
Population-based screening programs for identifying
undiagnosed individuals have a long history in improv-
ing public health. Examples include screening pro-
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grams for cancer (e.g., cervical, breast, colon), tuber-
culosis and fetal abnormalities. While the primary ob-
jective of such programs is to identify and treat undi-
agnosed individuals, these cancer screening programs
and the population-level, longitudinal datasets associ-
ated with them, present many opportunities for the
data-driven, computational sciences. In conjunction
with modern analytic and computational techniques,
such data have the potential to yield novel insights into
the natural history of diseases as well as improving the
effectiveness of the screening programs.
Hidden Markov Models (HMM) are a standard choice
for disease progression modeling for at least three rea-
sons. First, the underlying disease is represented as
an unobserved, latent Markov process. Second, noisy
measurements of the disease states are efficiently incor-
porated as conditional probability distributions in the
emission mechanism. Third, any modeling assump-
tions for a particular application are easily incorpo-
rated into the transition probability matrix and emis-
sion mechanism.
However, standard HMMs assume that measurements
are regularly sampled at discrete intervals which is of-
ten not the case in disease screening programs. Mea-
surements are often irregularly sampled because pa-
tients come in for screenings at irregular intervals,
even if regular screening tests are recommended. To
deal with irregular sampling, Continuous-Time Hid-
den Markov Models (CTHMM) are often used since
they easily handle samples taken at arbitrary time in-
tervals. CTHMMs have been proposed in many appli-
cations such as networks (Wei et al., 2002), medicine
(Bureau et al., 2003), seismology (Lu, 2017) and fi-
nance (Krishnamurthy et al., 2018). Liu summarizes
current inference methods for CTHMMs in Liu et al.
(2015) and proposes efficient EM-based learning ap-
proaches.
Because the natural history of many diseases de-
pends heavily on the age of the individual, the time-
homogeneous assumption is not valid. For this reason,
time-inhomogeneous HMMs are more appropriate. Al-
though such models have many appealing theoreti-
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cal properties according to the Kolmogorov equations
(Zeifman and Isaacson, 1994), parameter inference is
intractable in most non-trivial cases. For this rea-
son, many inference studies of continuous-time, time-
inhomogeneous HMMs (CTIHMMs) in the medical
domain depend on inefficient microsimulations (Son-
nenberg and Robert, 1993; Myers et al., 2000; Canfell
et al., 2004)
Because of the computational issues, many previous
HMM models of disease progression assume that the
observations come from a homogeneous population. In
large populations, this will typically not be the case.
For example, in population-level screening data a large
proportion of individuals have benign test results while
only a small proportion have abnormal test results.
Frailty models are proposed as a common methodology
in epidemiological modeling (Yen et al., 2010).
To deal with these difficulties we introduce piece-wise
constant transition intensity functions, which allow
for tractable parameter inference yet are considerably
more flexible in terms of time-inhomogeneity. We then
propose a latent structure (i.e., frailty model) to cap-
ture unobserved population heterogeneity in terms of
disease exposure and susceptibility. Specifically, we
propose a new hierarchical hidden Markov model for
disease progression in which patients are categorized
into classes based on risk levels. Due to the expen-
sive cost of the standard EM algorithm inference, we
propose an efficient and scalable EM algorithm com-
bining both soft and hard assignment in the E-step and
an auto-differentiation based Limited-memory BFGS
optimization method in the M-step.
We apply this model to cervical cancer screening data
from the Cancer Registry of Norway. This is a true
population-level dataset with over 1.7 million women
and more than 10 million screening results. Based
on the cervical cancer screening data, our model is
demonstrated to have better predictive accuracy com-
pared with state of the art recurrent neural network
models, based on AUC (Area Under the Curve) un-
der a binary classification framework. Moreover, our
model is significantly better than a simple hidden
Markov model by comparing model-generated Kaplan-
Meier curves with observed Kaplan-Meier curves.
2 Related Work
Longitudinal observation data exist widely, especially
in the healthcare area. Simpson et al. (2013) proposed
multiple self-controlled case series to model the mul-
tiple drug exposure based on conditional poisson re-
gression. Bao et al. (2017) extends it from discrete
time to continuous time using Hawkes process model-
ing. Moreover, Kuang et al. (2017) propose baseline
regularization to leverage the diverse health profiles
for adverse drug events. It is also a generalized linear
model extended from Kuang et al. (2016).
For a screening test, the health status is of interest.
It is crucial to consider a latent model of health sta-
tus. The hidden Markov model is the state of the art
approach. Most hidden Markov model variants con-
sider only discrete time (Gael et al., 2009; Beal et al.,
2002; Subakan et al., 2014). Continuous time hidden
Markov models can handle data at any time stamp
(Cox, 2017) and therefore are suitable for irregularly-
sampled longitudinal data (Bartolomeo et al., 2011;
Liu et al., 2013; Wang et al., 2014). Furthermore, Liu
et al. (2015) summarizes and discusses learning ap-
proaches for continuous time hidden Markov models
and proposes efficient EM-based learning approaches.
Since screening processes significantly depend on a pa-
tient’s age, our model is based on a CTIHMM, which
is discussed in Sonnenberg and Robert (1993), Myers
et al. (2000) and Canfell et al. (2004).
A modified transition matrix is generally modeled
by letting the transition distribution depend on a
set of observed covariates or exogenous time-series
via a multinomial logistic function (Hughes et al.,
1999; Meligkotsidou and Dellaportas, 2011; Paroli and
Spezia, 2008). Our transition distribution is derived
from the jump Markov process using the Kolmogorov
equations. While the parallelization of EM algorithms
for hidden Markov models has been studied (Mitchell
et al., 1995; Li et al., 2008), to the best of our knowl-
edge, there is no literature on efficient inference for
continuous-time, time-inhomogeneous hidden Markov
models. In this paper we propose a scalable EM algo-
rithm for the efficient inference of such models, which
is much more efficient than a nave or straight forward
implementation of a standard EM algorithm.
3 Model
We propose a hierarchical inhomogeneous HMM
(HIHMM) to model disease progression. The hier-
archical graphical representation is illustrated in Fig-
ure 1. In our real world case study, Z = 2 as we assume
all patients come from two risk categories: high disease
exposure risk and low disease exposure risk. Each cat-
egory has its own Markov model shown in Figure 2.
Details are discussed in Section 5. This hierarchical
structure of the HIHMM allows for an arbitrary num-
ber of latent frailty states, provided relevant Markov
models can be ascribed to the disease progression as-
sociated with each.
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Figure 1: Graphical representation for hierarchical in-
homgeneous hidden Markov models.
3.1 Variables
Suppose there are N individuals in the screening pop-
ulation. Let individual n have Tn screening visits at
ages a1, . . . , aTn . We assume Z categories are consid-
ered in the hierarchical frailty structure and introduce
the following variables:
Frailty State (hidden):zn ∈ {1, . . . , Z}
Disease States (hidden):Snt ∈ {1, . . . ,Mzn}
Number of screening tests (observable):Entk ∈ N
Screening test results (observable):Gntk ∈ NLk
The underlying disease state of individual n is as-
sumed to evolve according to a continuous-time, time-
inhomogeneous Markov process assigned by its latent
frailty class indicator zn, where only screening re-
sults at specific time stamps with corresponding ages
a1, . . . aTn are observable. On the tth screening visit of
individual n, Snt refers to the latent disease state and
the visit includes Entk tests of the kth test type and
the corresponding results Gntk, which is a Lk dimen-
sional vector and the value on lth dimension refers to
the number of the lth grade results.
3.2 Model of Disease Progression
As for the zth underlying Markovian disease process,
it is parameterized by an Mz×Mz transition intensity
matrix Qz. For the simplicity of notation, we ignore
the subscript z in the remainder of this section. The
ijth element qij of Q satisfies qij ≥ 0 for i 6= j and
qii = −
∑
i 6=j qij . The time spent in state i is ex-
ponentially distributed with rate −qii. Given that a
transition occurs from state i, the probability of tran-
sitioning to state j is
qij
qi
where qi =
∑
i 6=j qij . When
Q is invariant for time t the model is homogeneous,
otherwise the model is inhomegeneous.
3.2.1 Homogeneous Markov Model
For a homogeneous Markov process, we assume the
initial state at t0 is known, p(S(t1)) = 1. We let
t′ = (t′1, . . . , t
′
T ′) refer to the underlying transition
timestamps and let O = (O1, . . . , OT ) denote obser-
vations at time t = (t1, . . . , tT ). Then the complete
likelihood (CL) is given by
CL =
T ′∏
i=1
(qS(t′i),S(t′i+1)/qS(t′i))qS(t′i)e
−qS(t′
i
)Mi
T∏
j=1
p(Oj |S(tj))
=
M∏
i=1
e−qiτi∏
j 6=i
q
nij
ij
 T∏
j=1
p(Oj |S(tj)) , (1)
where M˜i = t˜i+1 − t˜i and nij denotes the number of
times the state changes from state i to state j dur-
ing the whole process and τi denotes the duration
that the process stays in state i. Since the underly-
ing transition timestamps t′ are not observable, the
marginalized complete likelihood (MCL) is derived by
marginalizing all t′ as
MCL =
T−1∏
i=1
P (Mi)S(ti),S(ti+1)
T∏
j=1
p(Oj |S(tj)) ,
where Mi= ti+1−ti and P (Mi) = eQMi is the transition
probability matrix from time ti to time ti+1.
3.2.2 Inhomogeneous Markov Model
An inhomogeneous Markov process drops the time in-
variance assumption of Q by allowing Q to be a func-
tion of t. CL then becomes intractable, because the
time spent in state i no longer follows an exponen-
tial distribution. An alternative approach is to con-
sider the MCL. The only difference in the expression of
MCLs between homogeneity and inhomogeneity is the
computation of the transition matrix P ([ti, ti+1]) from
time ti to time ti+1 for i = 1, . . . , T − 1. For the inho-
mogeneous model, P ([ti, ti+1]) = exp{
∫ ti+1
ti
Q(t)dt}.
The transition intensity function Q(t) can be mod-
eled by any parametric model, but the computation
of the matrix exponential exp{∫ ti+1
ti
Q(t)dt} may be
prohibitively expensive, even taking advantage of nu-
merical computational methods. To ease this com-
putational burden, we propose a piecewise constant
transition intensity matrix Q, where each element qij
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is a piecewise constant function of time. Specifically,
we partition time into I disjoint intervals covering
the range of observable time. We then have a set
of disjoint partitions A = {Ai}Ii=1. Each transition
intensity function qij is a piecewise constant func-
tion via the defined partition A, denoted by qij(t) =∑I
k=1 qijk1Ak(t), where 1(·) is an indicator function
and qij` ≥ 0. In this case, the inhomogeneous Markov
process can be treated as a combination of several
continuous-time homogeneous Markov processes, and
the transition probability matrix Q can be computed
as a product of transition probability matrices with
respect to their corresponding partitions.
3.3 Hierarchical Model
Due to the significant population heterogeneity related
to disease exposure risk, we propose a hierarchical
model as follows. Let ψ = (ψ1, . . . ,ψZ) denote all
model parameters and ψz be parameters for model z.
Then the hierarchical model is given by
On ∼ Mzn(ψzn ,θn) ,
zn ∼ Cat(p) ,
where θn denotes all covariates for individual n. An
informative prior of the model indicator zn is proposed
as a categorical distribution with hyper-parameters
p, which is used to provide expert knowledge of the
model assignment. This prior contributes to reason-
able model inference, especially when screening data
are highly unbalanced in terms of latent class mem-
bership. Figure 2 shows the case where Z = 2 and
index zn has a Bernoulli prior with a parameter p, i.e.,
zn ∼ Ber(p).
4 Inference
Due to the latent characteristics of both model in-
dices and patient states, the expectation maximiza-
tion (EM) approach is considered. Our EM alogrithm
employs the true conditional posterior for model in-
dex and the pseudo-conditional posterior for states in
the E-step. Both hard-assignment and soft assignment
approaches are studied in literature but they are not
combined. We balance the advantages of both meth-
ods for inference. Specifically, considering the het-
erogeneity of our model, we marginalize the latent
transition timestamps in our inference. We decom-
pose the joint posterior distribution as p(zn,Sn|−) =
p(zn|−)p(Sn|zn,−), where − denotes all other param-
eters and use soft assignment for p(zn|−) and hard
assignment for p(Sn|zn,−), because the computation
of p(Sn|zn,−) is prohibitively expensive. For simplic-
ity, we ignore covariates θn in the remainder of this
section.
The recursive procedures are given as follows:
• Given previous estimates ψ(t−1), compute the
conditional posterior distribution of zn:
p(zn|On,ψ(t−1)) ∝ Cat(zn|p)p(On|zn,ψ(t−1)zn )
∼ Cat(p˜n) , (2)
where p˜nk =
pkp(On|zn=k,ψ(t−1)k )∑Z
z=1 pzp(On|zn=z,ψ(t−1)z )
for k =
1, . . . , Z and p(On|z,ψz) is accessible through
the forward-filter backward-sample algorithm
(FFBS), which is a sequential Monte Carlo ap-
proach first proposed in Kitagawa (1987).
• Update the optimal state sequence Sn given cor-
responding observations On and model indicator
z using the Viterbi algorithm (Forney, 1973):
S(t)nz = Viterbi(On,ψz) . (3)
• Maximize the expected marginal complete log-
likelihood (EMCLL) with respect to ψ by
ψ(t) = arg max
ψ
N∑
n=1
Ezn,Sn(`(ψ|On, zn,Sn)|On,ψ(t−1))
= arg max
ψ
N∑
n=1
Z∑
z=0
p(zn = z|On,ψ(t−1))
(log pz + log p(Sn|z,ψ) + log p(On|Sn,ψ)) .
(4)
Since population screening datasets can contain mil-
lions of records, direct inference may be prohibitively
expensive and more scalable approaches are necessary.
We scale our EM algorithm by parallelizing the infer-
ence across observations using N˜ clusters, {Cn}N˜n=1, in
three parts. We first compute the conditional posterior
distribution of zn in each cluster using (2). The time
complexity for each cluster is O(|Cn|ZM2T ) (Khre-
ich et al., 2010). We then compute the optimal state
sequences in each cluster Cn using (3) with the same
time complexity O(|Cn|ZM2T ) (Backurs and Tzamos,
2016). Finally, we compute the gradients in each clus-
ter then reduce all local gradients to global gradients
for the optimization in the M-step. In detail the EM-
CLL is rewritten as
N∑
n=1
Ezn,Sn(`(ψ|On, zn,Sn)|On,ψ(t−1))
=
N˜∑
n˜=1
∑
n∈Cn˜
Ezn,Sn(`(ψ|On, zn,Sn)|On,ψ(t−1)).
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Taking gradient on both sizes, we have
∂
∂ψ
N∑
n=1
Ezn,sn(`(ψ|On, zn,Sn)|On,ψ(t−1))
=
N˜∑
n˜=1
∂
∂ψ
∑
n∈Cn˜
Ezn,Sn(`(ψ|On, zn,Sn)|On,ψ(t−1)).
Automatic differentiation (AD) (Baydin et al., 2018)
is utilized to compute the gradients in each cluster.
Summing over all clusters, we get the gradient of the
EMCLL. Using this gradient we adapt the Limited-
Memory BFGS (Liu and Nocedal, 1989) algorithm to
estimate ψ. Analytically computing the complexity of
the L-BFGS algorithm for each cluster is intractable,
but the paralleled algorithm increases inference speed
around N˜ times.
5 Experimental Results
The HIHMM is demonstrated on a true population-
level cervical cancer screening test dataset from the
Cancer Registry of Norway. Data used in the analyses
will be available on request from the Cancer Registry
of Norway, given legal basis according to the GDPR.
This dataset contains 1.7 million patients’ screening
testing records. Each patient has a censored observa-
tion at the last time stamp tc, denoted by Oc, which in-
dicates whether the woman is dead or alive at time tc.
Each patient has treatment indices to show when and
how many treatments occurred, and results of screen-
ing tests for each of cytology, histology and hpv. Cy-
tology and histology have four levels of outcomes while
hpv has two levels.
We set Z = 2 and the model processes are displayed
in Figure 2. For model z, the initial state is modeled
as Sz1|a1 ∼ Cat(piz(A, a0)) and pizi ∼ Dir(αzi), where
a1 denotes the age at the first screening test and A is
a disjoint partition of observable ages, piz(A, a) = pizi
if and only if a ∈ Ai, and αz` ∈ R+Mz .
The observations O have two levels: the number of
screening tests E and the results of screening tests
G. Omitting the subscripts n and t, given state s,
observations are modeled as
Ek ∼ Poisson(ηsk) ,
Gk|Ek ∼ Multinomial(Ek, p˜isk) ,
p˜isk ∼ Dir(α˜sk) ,
where α˜sk ∈ R+Lk are hyper-parameters for observa-
tion model. The censored observations (dead or alive)
are modeled by
p(Oc|ST ) =
{
P (tT , tc)ST ,death if Oc = death ,
1− P (tT , tc)ST ,death if Oc 6= death .
Normal Low grade
Death
Normal Low grade
Death
High grade Cancer
Figure 2: Transition structure of model M0 and M1.
Solid lines denote the intensity transition while dashed
lines denote that any state comes back to the normal
state once treatment is completed.
We choose the age partition as A as [0, 23), [23, 30),
[30, 60) and [60,∞). More details are available in the
supplementary material, including treatment modeling
and inference , age partition selection, model training
and optimization, which are all available in the Ap-
pendix.
In the proposed learning approach, we set the number
of EM iterations at NEM = 100, and in the Limited-
memory BFGS (L-BFGS) approach we set the num-
ber of optimization iterations as NL−BFGS = 8. Au-
tomatic differentiation is implemented using the auto-
grad package (Maclaurin, 2016) in Python.
5.1 Model Comparison
We randomly select 80000 patients’ records for train-
ing and select another 20000 records for testing. The
goal is to predict the status at the last visit. Specifi-
cally, if a patient has at least one result whose level is
greater than 1, then the status is defined as high risk
denoted as 1. Otherwise, the status is defined as low
risk denoted as 0. Thus, the problem is defined as a
binary classification problem.
The prediction procedure is defined as follows. Af-
ter model training, let model parameter estimates be
ψˆ. Given new patient historical records O∗, compute
the predictive distribution of model index p(z∗|O∗, ψˆ).
Next, given model index z, compute the predictive
distribution of the state at the second to last visit
p(S∗T−1|z,O∗, ψˆ) derived from FFBS. Then the pre-
dictive distribution of the state of the last visit is
p(S∗T |O∗, ψˆ)
∑
z p(z
∗ = z|O∗, ψˆ)p(S∗T |z,O∗, ψˆ) and
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the predictive distribution of screening test results is
p(G∗T |O∗,E∗T , ψˆ) =
∑
s p(S
∗
T = s|O∗, ψˆ)p(G∗T |S∗T =
s,E∗T , ψˆ). Finally, the predictive distribution of
the last status is G∗ ∼ Ber (p∗), where p∗ =
p
(∑1
i=0
∑3
j=2G
∗
T [i, j] ≥= 1|O∗,E∗T , ψˆ
)
. and it is es-
timated by Gˆ∗ =
{
1 p∗ ≥ 0.5
0 otherwise
. And the similar
procedures are available for the CTIHMM.
Recurrent neural network models (RNN) have been
found to perform well with variable-length time se-
ries and capture the temporal correlation well, because
of their flexibility and lack of the Markov property.
Variants of RNNs have been proposed to better bal-
ance memory needs and new features. Hochreiter and
Schmidhuber (1997); Cho et al. (2014) propose the
concept of a Long Short-Term Memory (LSTM) archi-
tecture, with variants utilized in handwriting recogni-
tion (Doetsch et al., 2014), language modeling (Mer-
ity et al., 2017), and video data (Zhang et al., 2016).
Chung et al. (2014) proposes the gated recurrent neu-
ral network (GRU) as another state of the art RNN
model. We compare RNN models with our proposed
model on the same prediction task to illustrate that
our model with interpretability outperforms RNNs on
those irregular samples. In details, each patient’s
record is modeled as one time-series and the features at
each visit includes patient’s age, patient’s screening re-
sult and patient’s treatment indicator. The screening
result of patient n at the tth visit is ~Gn,t. The treat-
ment indicator is equal to 1 if and only if the patient
has accepted treatment. LSTM (Cho et al., 2014),
stacked LSTM (Dyer et al., 2015) and GRU (Chung
et al., 2014) with different sizes are implemented for
model comparison. We propose small and large size of
models where small model refers to layer size 16 while
large model refers to layer size 64. For stacked LSTM,
two LSTMs are stacked. In the HIHMM, through cross
validation, the model prior is set as p = 0.001 and we
set 100 iterations in EM algorithm. In addition, we
set 10 iterations in EM algorithm as a fast inference.
In the CTIHMM, we also set 100 iterations in EM al-
gorithm. We summarize both prediction results and
training time in Table 1. It shows our model outper-
forms state of the art methods overall on the set of
criteria: Area Under the Curve (AUC), F1 value (F1),
Average Precision (AP) and Recall (R). Those metrics
related to recall score are important in clinic diagnosis,
it is better to mis-classify low-risk patient rather than
high-risk patient. Our model also have competitive
running time compared with neural network models.
5.2 Model Validation
Based on epidemiological studies, the incidence rate of
cervical cancer can provide us with guidance on how
to choose priors for the frailty rate of a given pop-
ulation (Bray et al., 2018). An informative prior is
indeed preferable here, so we set a conservative model
index prior p = 0.2. We note that there is always a
trade off between precision and recall, and p = 0.2
provides a reasonable balance based on model com-
parison results. We present two types of results on
population-level data. First we present the MLEs for
all model parameters along with bootstrapped stan-
dard deviations. Second we perform model validation
using Kaplan-Meier estimators as suggested in Titman
and Sharples (2008) and predictive accuracy via pro-
posed average posterior predictive probability.
We randomly divide all data into clusters such that
each cluster has 100 individual observation sequences.
Using a bootstrap technique, we randomly select 2400
clusters with replacement for model inference. We in-
dependently repeat the same inference on different se-
lections 5 times. The mean and standard deviation of
all parameter estimates are discussed in Appendix.
For model validation we randomly select 2400 clus-
ters of data in which each cluster has 100 individual
sequences of observations. We implement both the
HIHMM and the CTIHMM for the same dataset. We
follow the method proposed in Titman and Sharples
(2008) that utilizes Kaplan-Meier estimators to vali-
date continuous-time HMMs. Kaplan-Meier estima-
tors are defined according to the definition of a failure,
or time-to-event. In multi-state models different fail-
ures can be defined depending on which features of the
model and data are of interest. Here we define failure
as the first observation of a high-risk or cancer test
result directly following an initial normal or low-grade
test result. Accurately predicting this time-to-event is
of practical importance because clinical intervention is
only possible in the high-grade state. Treating patients
at this stage is critical to preventing precancerous le-
sions from progressing to cervical cancer.
The empirical Kaplan-Meier estimator is an important
criterion because it measures prediction on the whole
process rather than only the last visit, and it is defined
as Sˆ(t) =
∏
i:ti≤t (1− di/ni), where ti is a time when
at least one failure is observed, di is the number of fail-
ures that occurred at time ti, and ni is the number of
individuals known to have survived up to time ti. We
randomly choose 24000 records to generate an empiri-
cal Kaplan-Meier estimator according to our definition
of a failure. We generate Kaplan-Meier estimates by
simulating 100 sequences from both the CTIHMM and
HIHMM and repeat this 100 times. Figure 3 shows
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Table 1: Model prediction for the status of the last visit in terms of Accuracy (ACC), Area Under The
Curve(AUC), F1, Average Precision (AP), Precision (P), Recall (R).
Method ACC AUC F1 AP P R training time (h)
LSTM (small) 0.9905 0.4939 0.0000 0.0095 0.0000 0.0000 1.11
LSTM (large) 0.9925 0.8563 0.4275 0.2359 0.7778 0.2947 3.38
stacked LSTM (small) 0.9914 0.8561 0.2773 0.1273 0.6875 0.1737 2.26
stacked LSTM (large) 0.9926 0.8573 0.4335 0.2409 0.7808 0.3000 7.5
GRU (small) 0.9920 0.8379 0.4089 0.2083 0.6962 0.2895 0.79
GRU (large) 0.9921 0.8678 0.4207 0.2178 0.7037 0.3000 2.30
CTIHMM 0.9910 0.9128 0.3466 0.1465 0.5517 0.2526 3.61
HIHMM 0.9914 0.9190 0.5210 0.2774 0.5589 0.4895 6.97
HIHMM (fast) 0.9912 0.9268 0.5014 0.2583 0.5466 0.4632 0.90
the empirical Kaplan-Meier curve in black, simulated
Kaplan-Meier curves from the CTIHMM in blue, and
simulated Kaplan-Meier curves from the HIHMM. As
for the simulated Kaplan-Meier curves, solid lines de-
note the median curve and dashed lines denote the 95%
credible intervals based on the 100 replications. The
results show that the empirical Kaplan-Meier curve is
always near the median and within the 95% credible in-
tervals generated by the HIHMM. This is not the case
with the CTIHMM. In this sense the HIHMM outper-
forms the CTIHMM in an important clinical metric.
On the other hand, the HIHMM has a relatively high
Kaplan-Meier estimate at time 0 because the informa-
tive prior p = 0.2 is relatively small. This has the effect
of driving simulated patients to more likely be in the
low-risk modelM′ at the initial time. Moreover, these
patients are more likely to stay at the normal state for
longer. However, the trend of the median curve from
the HIHMM more closely tracks that of the empiri-
cal Kaplan-Meier curve, compared with the trend of
the median curve from the CTIHMM. This suggests
that the HIHMM models disease progression better
than the CTIHMM. The Kaplan-Meier curves simu-
lated from the CTIHMM are always underestimated.
We also propose average posterior predictive proba-
bility for Cytology, Histology and HPV at the last
visit given the screening tests as a quantitative mea-
surement for model validation. Specifically, for each
testing patient, its posterior predictive probabilities
are p(O∗T,test|O∗−T , ψˆ, E∗T ) where tests include Cytol-
ogy, Histology and HPV and model parameters ψˆ are
estimated via model training. We take 240000 patients
for training and 20000 patients for testing and model
validation results for CTIHMM and HIHMM are sum-
marized in Table 2.
Figure 3: Top panel: Empirical Kaplan-Meier curve
(black) and simulated Kaplan-Meier curves, which are
summarized using the 95% credible interval (dashed
lines) and the median (solid lines), from the CTIHMM
(blue) and HIHMM (red). Bottom panel: Posterior
probabilities of belonging to the frailty class for each
individual from a test set. Risk stratification is possi-
ble by thresholding the probabilities. Threshold prob-
abilities in this example are (0, 0.125, 0.25, 0.75, 1).
Color indicates falling between two probability thresh-
olds.
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Model Cytology Histology HPV
CTIHMM 0.9563 0.7597 0.6550
HIHMM 0.9571 0.7613 0.7010
Table 2: Average posterior predictive probabilities
of Cytology, Histology and HPV for CTIHMM and
HIHMM models
6 Conclusion and Discussion
One of the possible applications of the HIHMM in the
context of population-based screening programs is risk
stratification of the population. The latent random
variable zn is an indicator of belonging to a frail class in
the population. Given the learned model parameters
ψ it is possible to compute the posterior probability of
belonging to the frailty class for individual women. In
other words, given an observed sequence of test results
On and model parameters ψ, the posterior predictive
distribution p(zn|ψ,On) is of interest. This parame-
ter gives a measure of the likelihood of an individual to
be at risk of developing cervical cancer conditioned on
their observed test results. Such information could be
used to more efficiently screen a population by avoid-
ing the over screening of women at low-risk and the
under screening of women at high-risk.
Examples of these posterior probabilities are shown
in Fig 3. For illustration purposes, we have chosen
risk thresholds of {0.125, 0.25, 0.75} with the following
interpretation.
0 ≤ p(zn|ψ,On) < 0.125 =⇒ low-risk
0.125 ≤ p(zn|ψ,On) < 0.25 =⇒ unknown risk
0.25 ≤ p(zn|ψ,On) < 0.75 =⇒ medium-risk
0.75 < p(zn|ψ,On) ≤ 1 =⇒ high-risk
Two main clusters are apparent in the data corre-
sponding to unknown risk and high risk. The unknown
risk cluster is those patients close to the prior probabil-
ity of 20%. These patients lack sufficient observations
to make an informed decision about their risk profile.
This suggests these patients should be followed up with
the standard screening protocol. The high risk cluster
is those patients who are more likely to be in a high-
grade state. This suggests these patients may require
immediate follow up. The two smaller clusters of low
risk and medium risk are comprised of patients that
may require decreased or increased screening frequen-
cies, respectively, relative to the standard screening
protocol.
In summary, this paper has made the following contri-
butions:
• We model treatment effects in CTIHMM and
make CTIHMM inference possible for population-
level datasets by using piece-wise constant inten-
sity functions and deriving a scalable EM-based
inference algorithm.
• We put a hierarchical structure over the
CTIHMM to explain population heterogeneity in
terms of frailty but share the same states and their
emission probability, which makes the model more
practical, resulting in our HIHMM.
• We utilize prior distributions in the model to
achieve more accurate estimates when dealing
with imbalanced data.
• We perform full model inference and prediction
on subset of a cancer screening dataset and show
that our model outperforms comparators on the
prediction task.
• We perform full model inference on a cancer
screening dataset and show that modeling popula-
tion heterogeneity improves performance in terms
of Kaplan-Meier estimators and proposed average
posterior predictive probability.
• We illustrate how the model may be used to better
inform public health professionals by providing a
risk stratification mechanism.
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